Chronically elevated FGF23 drives sustained renal ERK signaling and inflammatory transcriptional programs mitigated by cFGF23 gene therapy

This study demonstrates that chronically elevated FGF23 levels drive sustained renal ERK signaling and inflammatory responses in chronic kidney disease, which can be effectively mitigated by C-terminal FGF23 (cFGF23) gene therapy.

The Gist

The Big Picture: A Hormone Gone Rogue

Imagine your body is a bustling city. In this city, there is a very important Foreman named FGF23. His main job is to manage the city's "mineral supply" (specifically, phosphate). When the city has too much phosphate, Foreman FGF23 sends a signal to the "Waste Management Department" (your kidneys) to flush the excess out.

In a healthy city, Foreman FGF23 works in short, sharp bursts. He sends a quick message, the job gets done, and he goes home. This is physiological (normal) signaling.

However, in people with certain kidney diseases or genetic conditions (like the mice in this study), Foreman FGF23 gets stuck on the job. He doesn't stop shouting orders; he screams them 24/7. This is chronic (chronically elevated) signaling.

The Problem: The "Red Alert" That Never Turns Off

The researchers discovered that when Foreman FGF23 screams orders non-stop, it breaks the kidneys' internal alarm system.

1. The Normal Signal (The Flash): When FGF23 works normally, it triggers a quick "flash" of activity inside the kidney cells (called ERK signaling). It's like a camera flash: bright for a split second, then gone. This tells the kidney to do its job and then relax.
2. The Broken Signal (The Siren): When FGF23 is stuck screaming, that "flash" turns into a siren that never stops. The kidney cells are stuck in a state of high alert.

The Consequence: Because the alarm never turns off, the kidney cells start panicking. They think they are under attack. They start building walls, calling in the "police" (immune cells), and shouting inflammatory messages. This leads to kidney inflammation, even if the kidney is still technically filtering blood okay. It's like a neighborhood that is constantly on high alert, leading to stress and damage, even if no actual crime has happened yet.

The Solution: The "Silencer" (cFGF23)

The researchers found a clever way to stop the screaming.

Foreman FGF23 has a "tail" (the C-terminal part). When the body breaks FGF23 down, this tail falls off. The researchers realized this tail acts like a silencer or a stop sign. It fits into the receptor's mouth and blocks the screaming Foreman from getting through.

• The Experiment: They used a gene therapy (a tiny viral delivery truck) to inject a massive amount of these "silencers" (cFGF23) into the sick mice.
• The Result: The silencers blocked the screaming Foreman. The "siren" in the kidney cells finally turned off. The inflammation stopped, and the kidney cells calmed down.

The "Two Faces" of the Signal

The study also showed something fascinating about how long the signal lasts:

• Short Signal (Normal): Triggers "Early Response" genes. Think of these as the Morning Crew. They wake up, do a quick task (manage minerals), and go back to sleep.
• Long Signal (Pathological): Triggers "Late Response" genes. Think of these as the Night Shift Riot Control. They stay awake for days, building barricades and calling for backup (inflammation).

The study proved that the "Night Shift" (inflammation) is only triggered when the signal is loud and long-lasting. A quick, normal signal never wakes up the riot control.

Why This Matters for Humans

This is a big deal for people with Chronic Kidney Disease (CKD) or genetic bone diseases like XLH.

• The Old View: Doctors thought high FGF23 was just a "symptom" or a "warning light" that the kidneys were failing.
• The New View: This paper suggests high FGF23 is actually part of the problem. It's actively causing inflammation and damaging the kidneys by keeping the "siren" on.

The Takeaway:
If we can block that screaming Foreman using the "silencer" (cFGF23 gene therapy), we might not just fix the mineral balance; we might also stop the inflammation that leads to heart disease and kidney failure. It's like turning off the fire alarm so the building stops panicking, rather than just trying to put out the fire.

Summary Analogy

Imagine a smoke detector in your house.

• Normal FGF23: The detector beeps once to tell you to check the toast. You check it, silence it, and life goes on.
• Chronic FGF23: The detector is broken and beeps continuously at 3 AM. The whole house is stressed, the neighbors are calling the police (inflammation), and the house is getting damaged from the stress.
• cFGF23 Therapy: You install a smart device that jams the signal, silencing the beeping. The house calms down, the neighbors stop calling, and the damage stops.

Technical Summary

1. Problem Statement

Fibroblast Growth Factor 23 (FGF23) levels are massively elevated in patients with Chronic Kidney Disease (CKD) and genetic disorders like X-linked hypophosphatemia (XLH). While high FGF23 is strongly associated with inflammation, cardiovascular disease, and mortality, the causal mechanisms remain unclear. Specifically, it is unknown whether chronically elevated FGF23 actively drives kidney inflammation or if it is merely a biomarker. Furthermore, the differential impact of acute/physiological versus chronic/pathological FGF23 levels on intracellular signaling dynamics (specifically ERK activation) and downstream transcriptional programs has not been characterized.

2. Methodology

The study employed a multi-faceted approach combining in vivo mouse models, in vitro cell culture, and transcriptomic analysis:

• In Vivo Model:
  • Subjects: Hyp-Duk mice (a murine model of XLH with lifelong elevated FGF23) and Wild-Type (WT) controls.
  • Intervention: Hyp-Duk mice were treated with an Adeno-Associated Virus (AAV) vector designed to secrete human C-terminal FGF23 (cFGF23) from the liver. cFGF23 acts as a natural antagonist by inhibiting FGF23 binding to its receptor complex.
  • Analysis: RNA sequencing (RNA-seq) of kidney tissue, urinary NGAL measurement (a marker of kidney injury), and deconvolution of immune cell populations.
• In Vitro Model:
  • Cell Lines: HEK293 cells (HEKwt) lacking Klotho and HEK293 cells stably transfected with Klotho (HEKkl). This allowed for the isolation of Klotho-dependent FGF23 signaling.
  • Stimulation: Cells were treated with:
    • Physiological dose: 0.5 nM FGF23 for 1 hour (mimicking acute/low levels).
    • Pathological dose: 10 nM FGF23 for 24 hours (mimicking chronic/high levels).
  • Inhibitors: Treatment with FGFR inhibitor (PD173074), MEK/ERK inhibitor (U0126), and recombinant cFGF23 peptide to block specific signaling nodes.
• Omics & Bioinformatics:
  • Bulk RNA-seq followed by Differential Gene Expression (DEG) analysis.
  • Gene Ontology (GO) enrichment and pathway analysis (ImmPort database intersection for immune signatures).
  • Bulk deconvolution using single-cell reference datasets to infer immune cell infiltration.

3. Key Contributions

• Mechanistic Distinction: The study establishes that chronically elevated FGF23 induces sustained ERK signaling, whereas physiological levels induce only transient ERK signaling.
• Transcriptional Divergence: It identifies that sustained ERK activation specifically upregulates "late-ERK targets" (e.g., ETV4/5, SPRED1/2, SPRY2/4) and inflammatory gene signatures, distinct from the "early-ERK targets" (e.g., EGR1, JUNB) triggered by acute signaling.
• Therapeutic Validation: It demonstrates that cFGF23 gene therapy effectively mitigates both the sustained ERK signaling and the resulting inflammatory transcriptional programs in the kidney.
• Klotho Dependence: It confirms that the pro-inflammatory effects of FGF23 in the kidney are strictly dependent on the Klotho co-receptor, as they were absent in Klotho-negative cells.

4. Key Results

A. In Vivo Findings (Hyp-Duk Mice)

• Signaling Dynamics: Hyp-Duk kidneys exhibited sustained ERK activation (evidenced by upregulation of late-ERK targets like Etv4, Stat3, Ets1) but no change in early-ERK targets.
• Inflammation: RNA-seq revealed significant upregulation of inflammatory and immune response pathways (e.g., Ras signaling, complement activation, NF-κB). Immune deconvolution showed an increased fraction of immune-like cells in Hyp-Duk kidneys.
• Therapeutic Rescue: AAV-mediated cFGF23 delivery in Hyp-Duk mice:
  • Restored canonical mineral metabolism genes (e.g., Slc34a1, Kl).
  • Reversed the upregulation of late-ERK targets and inflammatory genes.
  • Significantly reduced the inferred immune cell fraction.
  • Lowered urinary NGAL levels, indicating reduced kidney injury/inflammation.

B. In Vitro Findings (HEK293 Cells)

• Temporal Signaling:
  • Physiological (0.5 nM, 1h): Induced transient pERK1/2 and high expression of early targets (EGR1, FOS, JUNB).
  • Pathological (10 nM, 24h): Induced sustained pERK1/2 (persisting at 24h) and upregulated late targets (ETV1/4/5, SPRED1/2, SPRY2/4).
• Transcriptomic Profiles:
  • Pathological FGF23 treatment in HEKkl cells (but not HEKwt) induced a robust transcriptomic response including 88 unique DEGs.
  • These DEGs included specific inflammatory signatures (e.g., TNFRSF9/12A, GDF15, ANXA1, TGFB1) that overlapped with the Hyp-Duk mouse kidney profile.
• Mechanism of Action:
  • FGFR/ERK Inhibition: Pretreatment with FGFR or MEK inhibitors completely blocked the upregulation of both early/late ERK targets and inflammatory genes.
  • cFGF23 Antagonism: Recombinant cFGF23 peptide dose-dependently blocked FGF23-induced upregulation of inflammatory targets and ERK targets, confirming that blocking the FGFR-Klotho complex prevents the inflammatory cascade.

5. Significance and Implications

• Paradigm Shift: The study moves beyond viewing FGF23 solely as a mineral metabolism regulator, identifying it as a direct driver of renal inflammation via sustained ERK signaling when chronically elevated.
• Therapeutic Strategy: The results validate cFGF23 gene therapy as a potent strategy to counteract the adverse inflammatory effects of high FGF23 in CKD and XLH, potentially offering benefits beyond phosphate correction (e.g., reducing cardiovascular and renal inflammation).
• Clinical Relevance: The findings suggest that the subclinical kidney injury and inflammation observed in XLH patients and CKD patients may be driven by FGF23-mediated sustained ERK signaling. This provides a mechanistic rationale for targeting the FGF23-Klotho axis to treat inflammatory comorbidities in these populations.
• Model Utility: The study validates the HEK293-Klotho cell line as a robust in vitro model for studying renal FGF23 transcriptomics, bridging the gap between cell culture and complex in vivo physiology.

In conclusion, the paper elucidates that chronic FGF23 elevation triggers a specific sustained-ERK signaling cascade leading to renal inflammation, a process that is effectively mitigated by cFGF23 gene therapy through the competitive inhibition of the FGFR-Klotho complex.